TP53 and neoplasm: When 5-Aza and ITF-2357 were used, the authors saw a significant reduction in tumor burden across three xenograft models, two for established NSCLC cell lines and one for a KRAS, KDR, TP53 mutant primary patient-derived xenograft (PDX) model.